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Background: In potentially inappropriate medications harm potentially outweighs benefits.
Even appropriately prescribed medications may become inappropriate. They can lead to a
high risk of adverse drug reactions, morbidity and mortality. The aim of this study was to
determine the prevalence of potentially inappropriate medication in the older adult popula-
tion attending primary care in Portugal and to identify associated sociodemographic and
clinical factors.
Methods: We conducted a cross-sectional, analytical study in primary care centres from the
five Portuguese healthcare administrative regions and the two autonomous regions. We used
a random sample of 757 older patients provided by the information department of the
ministry of health (SPMS) and family doctors from the autonomous regions. Data collection
occurred March 2018 and we studied sociodemographic characteristics, clinical profile and
medication. We used 2015 Beers Criteria to assess potentially inappropriate medications.
Logistic regression analyses were performed to determine associations between potentially
inappropriate medications’ prescriptions and other variables.
Results: Potentially inappropriate medication was present in 68.6% and 46.1% of the sample
had two or more. The likelihood of having potentially inappropriate medication increased
significantly with being female (OR=1.56 [1.05 to 2.31]), number of chronic health problems
(OR=1.06 [1.01 to 1.13]), number of pharmacological subclasses (OR=1.40 [1.30 to 1.51])
and number of prescribers (OR=1.34 [1.09 to 1.65]). Proton-pump inhibitors, nonsteroidal
anti-inflammatory drugs and benzodiazepines were the most commonly found ones.
Conclusion: Potentially inappropriate medication in older adults was found to be a common
occurrence in Portugal. It is important that doctors are aware of this problem, namely in the
primary care setting due to the longitudinal care.
Keywords: potentially inappropriate medication, aged, polypharmacy, multimorbidity
Background
Potentially inappropriate medications (PIM) are those in which harm potentially out-
weighs the benefits, namely those that are not indicated or lack evidence of efficacy and
those that do not align with patients goals/preferences and values.1 The importance of
this increases as people get older because of decreased hepatic and renal function that
changes the benefit/risk ratio of medications, so even when appropriately prescribed
medications can become inappropriate.2,3 An Australian study reported that 60 of 100
hospitalized patients had at least one PIM, leading to a high risk of adverse drug
reactions, morbidity and mortality.4 There is an international consensus about when to
Correspondence: Pedro Augusto Simões
ARS Centro, USF Pulsar, Rua Teófilo
Braga, nº 25 5º Dto, Coimbra 3030-076,
Portugal
Tel +351 239 968384396
Email pedro.augusto.simoes@ubi.pt
Patient Preference and Adherence Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com Patient Preference and Adherence 2019:13 1569–1576 1569
DovePress © 2019 Simões et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For





































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
start many medications that are safe and effective, but there
are no guidelines regarding the cessation of inappropriate
medications.5
Many medication screening tools were developed to aid
identification of PIMs in older adults and improve their
care.6–8 The medication screening tools can be divided into
explicit checklists (lists of medications to be avoided in older
adults) and implicit checklists (issues to be taken into account
before prescribing a medication).9 The most widely used are
Beers criteria10 and the STOPP/START criteria (STOPP-
screening tool of older persons potentially inappropriate pre-
scriptions/START-screening tool to alert doctors to right
treatment).11 The Medication Appropriateness Index is an
example of an implicit checklist.9
Older patients, particularly those aged 65 and over, are
more frequently diagnosed with more pathologies, multi-
morbidity, and conditions prone to involve more prescrip-
tion drugs.12,13
In Portugal, there are only studies about the prevalence of
PIM in some of its regions, none conducted nationwide.14,15
Themost recent study in a primary care health centre in north
of Portugal identified a 37.0% prevalence of PIM, more
frequent in women (40.7%) than in men (30.9%).14
The aim of this study was to identify the nationwide
prevalence of PIM in older adults, identified in primary




Cross-sectional study-details, definitions and methods
were previously published.16
The study was conducted in agreement with the prin-
ciples of the Declaration of Helsinki17 and received ethical
approval from University of Beira Interior and Portuguese
healthcare administrative regions Institutional Ethics
Committees. The reporting of this study conforms to the
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement.18
Sampling
Since there were 2.18 million older adults (≥65 years) in
Portugal and the national literature suggested that the
range of PIM is around 40% and the international litera-
ture around 60%, we assumed the rate to be over 50%
because of epidemiological concern for better evidence
and larger sampling. We estimated a sample of a minimum
742 patients for a 95% CI and a maximum precision error
of 5%. In agreement with the geographical distribution of
the Portuguese population aged 65 and older across the
five mainland healthcare administrative regions and the
two autonomous regions (Madeira and Azores), noted in
PORDATA,19 a random sample of 757 patients was pro-
vided by the information department of the ministry of
health, Serviços Partilhados do Ministério da Saúde
(SPMS), and invited family doctors from autonomous
regions, due to lack of digital databases within these last
regions.
Data Collection Procedures
Data collection occurred in March 2018 (data extracted on
March 30). In brief, the SPMS provided us with an electronic
file with the variables of the study from the randomly
selected (by patient’s national health number) sample of the
five healthcare administrative regions. This electronic file
contained anonymised information stored in the patient’s
electronic medical records. Since SPMS does not have access
to electronic medical records from patients in the two auton-
omous regions, we invited two medical doctors, one from
each autonomous region, to provide us with the needed
information. We studied the prescribed medications using
the mandatory nationwide, electronic prescription platform
(PEM).20 There is an unknown number of over the counter
medications consumed by the Portuguese population and as
they can be bought without prescription, there is no way to
access this information. SPMS could not provide us with
information regarding the level of education, since in most
cases it was missing from medical records.
Outcome Variable
For each patient, PIM was measured as the presence of one
or more drugs, that are inappropriate for older patients,
according only to Table 2 of 2015 Beers Criteria.10
Independent Variables
Sociodemographic characteristics such as age, gender (male/
female), area of residence (in terms of health administrative
region), clinical profile (chronic health problems according
to International Classification of Primary Care, second edi-
tion – ICPC-2) and prescribed medication (from April 2017
to March 2018 and was encoded following the Portuguese
pharmacotherapeutic classification using the more discrimi-
nate level possible). The Portuguese pharmacotherapeutic
classification has similarities with the ATC (Anatomical
Therapeutic Chemical) classification and was adapted by
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INFARMED (National Authority of Medicines and Health
Products).21
Statistical Analysis
In addition to the descriptive analysis, χ2 tests were per-
formed for nominal qualitative characteristics. Lastly, we
performed a logistic regression with all the statistically
significant variables in previous χ2 tests. All tests were
two-sided using a significance level of 0.05. Statistical
analysis was conducted using SPSS V.24.0.
Results
Characteristics Of Participants
The sample consisted of 757 individuals; the mean age was of
75.5±7.9 years (75.1±7.9 years for men and 75.8±7.8 years for
women). Table 1 shows the characteristics of the sample.
Prevalence Of Potentially Inappropriate
Medication
More than 9 of 10 older patients of the sample (93.4%)
had at least 1 medication prescribed, with an overall aver-
age of 8.2 (95% CI 7.9 to 8.6), 7.5 (95% CI 7 to 8) in men
and 8.8 (95% CI 8.3 to 9.3) in women.
Potentially inappropriate medication was present in
68.6% (95% CI 65% to 72%) of the sample and 2 or
more PIMs were present in 46.1% (95% CI 42.5% to
49.7%), with an overall average of 1.76 (95% CI 1.63 to
1.89), 1.35 (95% CI 1.18 to 1.52) in men and 2.07 (95%
CI 1.88 to 2.26) in women.
According to Table 2, there was no significant relation-
ship between PIM and health administrative region. There
was a significant relationship between PIM and number of
chronic health problems, number of medications taken,
number of prescribers and with many of the ICPC-2
classes and pharmacological subclasses.
After adjustment, Table 3 shows that the likelihood of
having PIM increased significantly in females [OR=1.56
(1.05–2.31)], with number of chronic health problems
[OR=1.06 (1.01–1.13)], number of pharmacological sub-
classes [OR=1.40 (1.30–1.51)] and number of prescribers
[OR=1.34 (1.09–1.65)]. No differences in the odds of PIM
were associated with age [OR=0.99 (0.97–1.05)].
Chronic Health Problems/Pharmacological
Subclasses And Patterns Of PIM
Table 3 shows the odds ratio measured the impact of having
each specific chronic health problems (according to ICPC2).
Table 1 Characteristics Of The Sample













<75 years 51.5 (390)
≥75 years 48.2 (365)
























Number of Pharmacological Subclasses
0–4 drugs 23.1 (175)
5–9 drugs 39.0 (295)
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For patients suffering from chronic health problems related to
digestive, circulatory, musculoskeletal and respiratory sys-
tems, there are 1.4 times, 1.2 times, 1.3 times and 1.5 times,
respectively, greater probability of having a PIM when com-
paring to those not suffering from health problems related to
that specific system. Older adults taking medication from
central nervous system, digestive system and locomotive sys-
tem groups (according to Portuguese pharmacotherapeutic
classification) are 2.4 times, 4.9 times and 5.3 times, respec-
tively, more likely to have PIM than those not taking any drug
from that system group. The most common pharmacological
subclasses causing PIM were proton-pump inhibitors (present
in 45.6% of the sample), nonsteroidal anti-inflammatory drugs
(in 34.5%) and benzodiazepines (in 27.3%).
Discussion
Strengths Of The Study
This is the first study to report the prevalence and patterns
of PIM in older adults attending primary care consultations
nationwide in Portugal. It is a cross-sectional study with a
randomised sample, which is the most frequent design to
assess the prevalence and its characteristics. We used the
most discriminative chemical subgroup of the Portuguese
pharmacotherapeutic classification, to assess polyphar-
macy; this can minimize the bias of medical changes. We
also used active components according to 2015 Beers
Criteria10 for assessing PIM, since for some pharmacolo-
gical classes some active pharmaceutical ingredients are
potentially inappropriate while others are safe.
Since the data were obtained from SPMS on a nation-
wide scale, we could obtain a size representative sample of
the population, avoiding over-representation of the more
frequent users of primary care services, which could hap-
pen if the data were collected from GP records of most
frequent prescriptions.
Statement Of Overall Findings
The study results show a high prevalence of PIMs in the
Portuguese older population (68.6%), exceeding the
reported prevalence of other studies (11.5–62.5%).22 One
of the explanations can be the period of time we used in this
study (12 months), which can increase polypharmacy23 and
affect the number of PIM, making this high prevalence
misrepresentative of reality, since the medication could
have been ceased or not purchased. Given the lack of con-
sensus of classification for PIM,6 we used the list of drugs in
Table 2 of 2015 Beers Criteria. We used Beers Criteria
because it is the most commonly used tool to identify PIM
in the literature with regular updates.
We found no difference in risk of PIM with increasing
age. Our findings do not match those from other studies; most
of them found an increased risk of PIM in younger and older
ages.22,24 Since there are mixed results, more studies are
needed to assess this relation. One hypothesis for this dis-
crepancy is that there is a higher awareness of this problem in
overall patients with ≥65 years due to increased susceptibility
to adverse drug events, age-related drug–drug and drug–
disease interactions, making it possible to think that there is
no difference in pharmacological care in people equal and
older than 65 in Portugal as age increases.25
In line with previous reports,22 we found an increased
risk of PIM in women. We can hypothesise that women
tend to live longer and be more prone to have complaints,
either physical or psychological. More studies are neces-
sary to study this issue.
As expected, the number of medications affects the
number of PIMs, since with an increased number of
drugs there is an increased probability of adverse drug
reactions and drug–drug interactions. This association is
described in the literature.22,24,26
We found a difference in risk of PIM with the number of
comorbidities, showing the impact that multimorbidity also
affects the health of older adult population through the
increased risk of PIM.12 Our results again do not match
Table 1 (Continued).













Notes: A, general and unspecified; B, blood, blood forming organs, lymphatics,
spleen; D, digestive; F, eye; H, ear; K, circulatory; L, musculoskeletal; N, neurolo-
gical; P, psychological; R, respiratory; S, skin; T, endocrine, metabolic and nutritional;
U, urology; X, female genital system and breast; Y, male genital system; Z, social
problems; 2, central nervous system; 3, cardiovascular system; 4, blood; 5, respira-
tory system; 6, digestive system; 7, genitourinary system; 8, hormones and medica-
tions used to treat endocrine diseases; 9, locomotive system; 10, antiallergic
medication; 16, antineoplastic and immunomodulatory drugs.
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Table 2 Prevalence Of PIM According To Characteristics
Characteristic No PIM % (n) PIM % (n) p-Value (χ2 Test) Mean Number Of PIMs (95% CI) [Median]
Gender <0.001
Women 32.3 (139) 67.7 (291) 2.07 (1.88 to 2.26) [2]
Men 47.7 (156) 52.3 (171) 1.35 (1.18 to 1.52) [1]
Health Administrative Region 0.201
North 32.0 (78) 68.0 (166) 1.66 (1.44 to 1.89) [1]
Centre 31.1 (59) 68.9 (131) 1.85 (1.59 to 2.12) [1]
Lisbon-Tejo Valley 28.9 (58) 71.1 (152) 2.00 (1.75 to 2.26) [2]
Alentejo 37.9 (25) 62.1 (41) 1.38 (0.95 to 1.81) [1]
Algarve 44.1 (15) 55.9 (19) 1.32 (0.53 to 2.11) [1]
Madeira 42.9 (3) 57.1 (4) 0.57 (0.08 to 1.07) [1]
Azores 0 (0) 100 (6) 2.33 (1.25 to 3.42) [2]
Age 0.048
<75 years 34.6 (135) 65.4 (255) 1.70 (1.52 to 1.88) [1]
≥75 years 27.9 (102) 72.1 (263) 1.83 (1.64 to 2.03) [1]
Number of Chronic Health Problems <0.001
0–2 54.2 (71) 45.8 (60) 1.14 (0.85 to 1.42) [0]
3–4 43.8 (64) 56.2 (82) 1.40 (1.10 to 1.70) [1]
5–6 30.1 (40) 69.9 (93) 1.65 (1.33 to 1.96) [1]
7–8 18.9 (24) 81.1 (103) 2.08 (1.76 to 2.40) [2]
9–10 25.6 (23) 74.4 (67) 1.83 (1.47 to 2.20) [2]
≥11 12.3 (16) 87.7 (114) 2.55 (2.22 to 2.89) [2]
Chronic Health Problems (ICPC2)
A 22.4 (19) 77.6 (66) 0.063 2.07 (1.66 to 2.49) [2]
B 24.6 (14) 75.4 (43) 0.299 1.91 (1.40 to 2.43) [1]
D 21.0 (58) 79.0 (218) <0.001 2.14 (1.90 to 2.38) [2]
F 27.1 (42) 72.9 (113) 0.208 2.06 (1.74 to 2.37) [2]
H 21.8 (19) 78.2 (68) 0.049 2.21 (1.80 to 2.61) [2]
K 29.1 (171) 70.9 (416) 0.012 1.82 (1.67 to 1.97) [1]
L 23.2 (91) 76.8 (301) <0.001 2.06 (1.86 to 2.25) [2]
N 21.8 (26) 78.2 (93) 0.018 2.29 (1.93 to 2.65) [2]
P 22.7 (59) 77.3 (201) <0.001 2.21 (1.97 to 2.46) [2]
R 19.8 (35) 80.2 (142) <0.001 2.19 (1.91 to 2.47) [2]
S 27.4 (40) 72.6 (106) 0.275 1.72 (1.45 to 1.99) [1]
T 27.9 (145) 72.1 (374) 0.002 1.83 (1.67 to 1.99) [1]
U 23.3 (38) 76.7 (125) 0.013 1.94 (1.67 to 2.20) [2]
X 18.1 (13) 81.9 (59) 0.011 2.22 (1.79 to 2.66) [2]
Y 28.7 (33) 71.3 (82) 0.515 1.67 (1.34 to 2.00) [1]
Z 14.8 (4) 85.2 (23) 0.089 2.30 (1.58 to 3.01) [2]
Number of Pharmacological Subclasses <0.001
0–4 drugs 73.7 (129) 26.3 (46) 0.35 (0.25 to 0.45) [0]
5–9 drugs 29.2 (86) 70.8 (209) 1.42 (1.27 to 1.58) [1]
≥10 drugs 8.0 (23) 92.0 (264) 2.97 (2.73 to 3.21) [3]
Pharmacological Classes (INFARMED)
2 17.9 (101) 82.1 (463) <0.001 2.21 (2.05 to 2.36) [2]
(Continued)
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those from other studies. Differences in the pharmacological
and health problems data collection could explain such
discrepancies.24,26 However, an increase number of comor-
bidities can lead to and can be the cause of an increase
number of prescribed drugs, increasing the risk of PIM.12
From the four ICPC-2 classes with high impact on the risk of
PIM according to our finding (digestive, cardiovascular,
musculoskeletal and respiratory problems), only the muscu-
loskeletal problems are described in the literature.26
In line with previous reports,27 more prescribers were
associated with higher risk for PIM. One hypothesis is that
prescribers may not be aware of all the medication the
patient is taking nor of the changes made by other pre-
scribers to the list of medication; this increases the risk of
duplicated drugs, adverse drug reactions, drug–drug inter-
actions and drug–disease interactions. On the other hand,
more complex patients (with multiple comorbidities) need
to be assisted by more doctors and take more drugs,
increasing the risk of PIM. This is of extreme importance,
since 17% of our older adults had 4 or more prescribers
within the last year. It is also important for previously
prescribed medication to be listed for everyone on the
national electronic drug prescription system (PEM).
According to previous reports,24,26 PPIs, NSAID and
benzodiazepines are among the most common PIM in the
older adult population in primary health care in Portugal.
Therefore, there is a need to quantify the resulting harms
for individuals, families and society, and to make its eco-
nomic and financial impact known to medical and lay
communities, in order to help deprescribing to become
easier for doctors and better accepted by patients.
Limitations Of The Study
There are some limitations of this study.
Firstly, we used a 12-month period to assess the chronic-
prescribed medication, which can increase the prevalence of
polypharmacy and PIM, since medication could have been
ceased or not purchased. Therefore, the number of medica-
tions, as well as the number of PIMs, per older adult may be
overestimated.
Secondly, since the SPMS could not give us data from
both autonomous regions (Madeira and Azores), represent-
ing 1.7% of the sample, data were collected by local GPs,
making the sample and collection data processes in these
two regions different from the rest. Nevertheless, rando-
misation was performed.
Thirdly, there was the intention of evaluating the effect of
level of education on polypharmacy. Such was not possible
due to lack of information in patient’s electronic records.
Fourthly, we only used Table 2 of 2015 Beers Criteria for
assessing PIM; therefore, PIM due to drug–disease and drug–
drug were not assessed due to the complexity of this analysis
and our 12-month period assessment of prescribedmedication.
Also, the Beers criteria were updated in April 2019, where
some drugs were eliminated from and others added to the
previous list (2015 Beers Criteria), but since at the time of
study (2018), the most recent list was 2015 Beers criteria we
kept them.
Table 2 (Continued).
Characteristic No PIM % (n) PIM % (n) p-Value (χ2 Test) Mean Number Of PIMs (95% CI) [Median]
3 26.0 (161) 74.0 (458) <0.001 1.94 (1.79 to 2.09) [2]
4 19.7 (55) 80.3 (224) <0.001 2.14 (1.91 to 2.37) [2]
5 18.1 (29) 81.9 (131) <0.001 2.43 (2.12 to 2.73) [2]
6 8.6 (33) 91.4 (350) <0.001 2.78 (2.58 to 2.98) [2]
7 28.0 (35) 72.0 (90) 0.400 1.89 (1.55 to 2.22) [1]
8 22.4 (72) 77.6 (250) <0.001 2.02 (1.80 to 2.23) [2]
9 10.3 (42) 89.7 (366) <0.001 2.51 (2.33 to 2.70) [2]
10 14.3 (22) 85.7 (132) <0.001 2.51 (2.22 to 2.81) [2]
16 8.3 (1) 91.7 (11) 0.117 2.83 (1.28 to 4.39) [2]
Number of Prescribers <0.001
≤2 42.8 (207) 57.2 (277) 1.24 (1.10 to 1.38) [1]
>2 11.4 (31) 88.6 (242) 2.69 (2.46 to 2.92) [2]
Notes: A, general and unspecified; B, blood, bloodforming organs, lymphatics, spleen; D, digestive; F, eye; H, ear; K, circulatory;L, musculoskeletal; N, neurological; P,
psychological; R, respiratory; S, skin;T, endocrine, metabolic and nutritional; U, urology; X, female genital systemand breast; Y, male genital system; Z, social problems; 2,
central nervoussystem; 3, cardiovascular system; 4, blood; 5, respiratory system; 6, digestivesystem; 7, genitourinary system; 8, hormones and medications used to
treatendocrine diseases; 9, locomotive system; 10, antiallergic medication; 16, antineoplasticand immunomodulatory drugs.
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Fifthly, the sample size was chosen to achieve a suffi-
ciently precise overall proportion estimate of PIMs in the
Portuguese older adults’ population, but not to find differ-
ences among different population strata.
Finally, this is a cross-sectional study and so no causal
relationship could be proven. However, we only intended
to raise questions and not determine causality, so other
studies are required to study causality, frequency and
outcomes.
Conclusion
This study found a high prevalence of PIM in the studied
sample; the most important factors were being female,
number of chronic health problems, number of pharmaco-
logical classes and number of prescribers.
It is important that doctors are aware of this problem,
namely in the primary care setting due to the longitudinal
profile of care in general practice.
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